• Publications
  • Influence
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
Background Following a clinical evaluation of deferasirox (Exjade®) it was concluded that, in addition to baseline body iron burden, ongoing transfusional iron intake should be considered whenExpand
  • 251
  • 8
  • PDF
Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia
Thalassemia intermedia is a highly diverse group of thalassemia syndromes associated with anemia and a range of specific complications, such as extramedullary hematopoiesis, leg ulcers, gallstonesExpand
  • 95
  • 7
Genetic Heterogeneity of Beta Thalassemia in Lebanon Reflects Historic and Recent Population Migration
Beta thalassemia is an autosomal recessive disorder characterized by reduced (β+) or absent (β0) beta‐globin chain synthesis. In Lebanon it is the most predominant genetic defect. In this study weExpand
  • 35
  • 7
  • PDF
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
This subgroup analysis evaluated the effect of once‐daily oral deferasirox on labile plasma iron (LPI) levels in patients from the prospective, 1‐yr, multicentre ESCALATOR study. Mean baseline liverExpand
  • 68
  • 5
Pregnancy outcome in patients with β-thalassemia intermedia at two tertiary care centers, in Beirut and Milan
β-thalassemia intermedia (TI) patients can present with a severe clinical disease at 2–6 years of age or remain asymptomatic until adult life. They suffer from mild anemia (hemoglobin (Hb) betweenExpand
  • 46
  • 5
Total white blood cell count is associated with the presence, severity and extent of coronary atherosclerosis detected by dual-source multislice computed tomographic coronary angiography.
BACKGROUND Total white blood cell (WBC) count has been consistently shown to be an independent risk factor and predictor for future cardiovascular outcomes, regardless of disease status in coronaryExpand
  • 52
  • 4
Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients
Summary. Desferrioxamine (DFX) alone (40–50 mg/kg/d s.c. over 8–12 h, five times weekly) was compared with combined DFX twice weekly and deferiprone (75 mg/kg/d) over 12 months in previously poorlyExpand
  • 121
  • 4
A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period.
Data of patients with acquired inhibitors to clotting factors seen in a haemophilia centre from 1970-98 was collected. Twenty-four patients with anti-factor VIII antibodies and four with acquired vonExpand
  • 69
  • 4
JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: experience of a major referral center in Lebanon.
AIMS JAK2 V617F mutation is gaining more acceptance in laboratory testing as part of the differential diagnosis work-up of myeloproliferative disorders (MPD). This report is the first of its kindExpand
  • 23
  • 4
Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics
Abstract Exposure to hepatitis C virus (HCV), hepatitis G virus (HGV) and the carrier 'rate' for hepatitis B virus (HBsAg) were investigated in thalassaemia patients in Lebanon, a group that has notExpand
  • 42
  • 3